IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#2125
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$4.9B
Stuart W. Peltz
PTC Therapeutics focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States; Tegsedi and Waylivra for the. treatment of rare diseases in Latin America and the Caribbean. PTC518 is being developed for Huntington's disease.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = PTCT ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$PTCT PTC THERAPEUTICS, INC. | 49 | 39 | 49 | 65 | 8.0x | 6.4x | -124.2% | 24.5% | 100.0% | 9.2% | -2.3% | 13.0% | 0.0% | - | $4.9B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
PTC THERAPEUTICS, INC. (PTCT) receives a "Reduce" rating with a composite score of 49.2/100. It ranks #2125 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Direct cash return
Stuart W. Peltz
Chief Executive Officer
Labor Force
1,410
39
32
71
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for PTCT
Outperforming peers — winners tend to keep winning over 3-12 months
Fair valuation relative to peers
Average quality profile
Low volatility — smoother ride and historically better risk-adjusted returns
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for PTCT.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
ROE proxy -124.2% (sector -2.5%)
GM 100% vs sector 43%, OM 9% vs sector 1%
Capital turnover N/A, R&D intensity 26.3%
Rev growth 13%, 10yr history
Interest coverage N/A, Net debt/EBITDA -0.4x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
PTC THERAPEUTICS, INC. receives a Reduce rating from our analysis, with a composite score of 49.2/100 and 2 out of 5 stars, ranking #2125 out of 7,333 stocks. PTCT's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
PTCT's quality score of 39/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -124.2% (sector avg: -2.5%), gross margins of 100.0% (sector avg: 42.5%), net margins of -2.3% (sector avg: -0.2%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 49/100, PTCT appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/E ratio of 7.98x, an EV/EBITDA of 6.42x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
PTC THERAPEUTICS, INC.'s investment score of 32/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 13.0% vs. a sector average of 5.9% and a return on assets of 24.5% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
PTCT demonstrates moderate momentum with a score of 65/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at 13.0% year-over-year, while a beta of 0.95 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
PTCT shows good financial stability with a score of 71/100. Key stability metrics include a beta of 0.95. This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.
PTC THERAPEUTICS, INC.'s short interest score of 31/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. At $4.9B (mid-cap), PTCT carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
PTC THERAPEUTICS, INC. is a mid-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #2125 of 7,333 overall (71st percentile). Key comparisons include ROE of -124.2% trailing the -2.5% sector median and operating margins of 9.2% above the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While PTCT currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Short Int. (31) would have the largest impact on the composite score.
EV/EBITDA 44% BELOW SECTOR MEDIAN (FAVORABLE)
ROE 4910% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 135% ABOVE SECTOR MEDIAN (FAVORABLE)
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate PTC THERAPEUTICS, INC. (PTCT) as a Reduce with a composite score of 49.2/100 at a current price of $69.02. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential and elevated risk of underperformance relative to peers over the next 12 months.
The rating is primarily driven by strength in stability (71th percentile) and momentum (65th percentile), which together account for the majority of the composite score. Offsetting weakness in investment (32th percentile) and quality (39th percentile) tempers our overall conviction. We assign a Narrow Moat rating (48/100), Medium uncertainty, and Poor capital allocation.
Key items to watch: the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
PTC THERAPEUTICS, INC. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 49.2/100 places it at rank #2125 in our full 7,333-stock universe. At $4.9B in market capitalization, PTC THERAPEUTICS, INC. is a mid-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
The outlook is moderately positive, with revenue expanding at 13% and favorable momentum (65th percentile) reflecting constructive market sentiment. The business shows steady execution, though the growth rate is below the levels typically associated with high-conviction growth stories. Momentum confirmation provides support for the current price level.
The margin cascade tells an important story: gross margins of 100% (+57.5pp vs sector) narrow to operating margins of 9% (+7.9pp vs sector) and net margins of -2.3%, yielding a gross-to-net conversion rate of -2%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $69.02, PTC THERAPEUTICS, INC. is trading near fair value based on current fundamentals. Our value factor score of 49/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
The stock currently trades at a P/E of 8.0x (a 64% discount to the sector median of 22.3x), EV/EBITDA of 6.4x (discounted to peers), P/S of 3.2x. The below-sector P/E suggests possible undervaluation or the market pricing in near-term headwinds.
Gross margins of 100% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Revenue growth of 13% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
Positive momentum (65th percentile) indicates institutional accumulation and favorable technical dynamics that tend to persist in the intermediate term.
Return on assets of 24.5% indicates efficient deployment of the full asset base, not just equity capital.
The Reduce rating (composite 49.2/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
We assign a Medium uncertainty rating to PTC THERAPEUTICS, INC.. The stock presents a balanced risk profile: current negative profitability (net margin -2.3%). While not risk-free, the core business fundamentals are adequate to withstand moderate economic stress, and the range of potential outcomes around our fair value estimate is manageable.
Specific risk factors that inform our assessment include: current negative profitability (net margin -2.3%). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 71th percentile and quality factor at the 39th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 100% provide a buffer against cost pressures; above-average stability (71th percentile) suggests predictable business dynamics. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.
We rate PTC THERAPEUTICS, INC.'s capital allocation as Poor. Key concerns include low returns on equity (-124.2%), negative profitability. Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — PTC THERAPEUTICS, INC. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, PTC THERAPEUTICS, INC. receives a Reduce rating with a composite score of 49.2/100 (rank #2125 of 7,333). Our quantitative framework assigns a Narrow Moat (48/100, trend: stable), Medium uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 51/100.
Our analysis does not support a constructive view on PTC THERAPEUTICS, INC. at this time. The combination of the current quantitative profile, medium uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We assign PTC THERAPEUTICS, INC. a Narrow Moat rating with a composite moat score of 48/100. The company possesses identifiable competitive advantages, though they are less entrenched than those of wide-moat peers. Our analysis indicates that PTC THERAPEUTICS, INC. can sustain above-average returns on invested capital for at least 10 years, with the strongest contributor being margin superiority at 18/20.
The strongest moat sources are margin superiority (18/20) and growth durability (12.1/20). GM 100% vs sector 43%, OM 9% vs sector 1%. Rev growth 13%, 10yr history. These pillars form the core of PTC THERAPEUTICS, INC.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (2.7/20) and reinvestment efficiency (7/20). ROE proxy -124.2% (sector -2.5%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect PTC THERAPEUTICS, INC.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 100% providing a solid profitability foundation, moderate revenue growth of 13%. The margin cascade from 100% gross to 9% operating to -2.3% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 39th percentile.
The margin profile shows gross margins of 100%, operating margins of 9%, net margins of -2.3%. Return metrics include ROE of -124.2% and ROA of 24.5%. Relative to the Manufacturing sector, gross margins are 57.5 percentage points above the sector median of 43%, and ROE of -124.2% compares to a sector median of -2.5%.
The balance sheet reflects revenue growth of 13%. Overall balance sheet health is adequate for the current business environment.
Thin net margins of -2.3% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
Above 50MA
37.18%
Net New Highs
+51081
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences:
PTC Therapeutics (PTCT) Q4 2025 earnings call highlights: Sephience launch momentum, 2026 revenue guidance, cash flow outlook, and key risks—read now.
PTC Therapeutics' CEO Matthew Klein highlighted the commercial potential of Sephience, a drug for treating phenylketonuria (PKU), projecting significant market opportunities in the U.S. and internationally. The company expects to reach cash flow breakeven with growing sales and believes most patients will respond positively to the treatment.
Analysts have adjusted their fair value estimate for PTC Therapeutics slightly lower, from US$88.50 to about US$87.93, keeping price targets clustered in the low to mid US$80s. This small move reflects how recent Street research is balancing optimism around Sephience with caution on DMD pressure and longer term growth visibility. As you read on, you will see how these shifting targets and narratives might shape how you follow PTC from here. Stay updated as the Fair Value for PTC Therapeutics...
Royalty Pharma has acquired the final portion of PTC Therapeutics' remaining royalty on Roche's Evrysdi for $240 million upfront plus up to $60 million in sales-based milestones. Following the transaction, Royalty Pharma will own 100% of the tiered 8% to 16% royalty on worldwide net sales of Evrysdi, an FDA-approved spinal muscular atrophy treatment that generated approximately $1.9 billion in sales in 2024 with projected growth to $2.9 billion by 2030.